drug

sibeprenlimab

1 story · latest Sep 3, 2026

Status: FDA approved Nov 2025 · BLA761434
Brand: Voyxact

Relationships

Developed by Otsuka Pharmaceutical

Timeline

Climb Bio reports Phase 1 data for anti-APRIL antibody CLYM116 in IgA nephropathy program

Sep 3Clinical readoutClimb Bio, Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.